Vertex's experimental pain drug fails main goal in mid-stage study
04/08/2025 21:06
Aug 4 (Reuters) - Vertex Pharmaceuticals VRTX.O said on Monday its next generation oral drug failed to meet the main goal of a keenly-watched mid-stage trial. (Reporting by Sriparna Roy and Padmanabhan Ananthan in Bengaluru; Editing by Leroy Leo) ((Sriparna.Roy@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals Incorporated
See all newsBrief: Vertex Appoints Daniel Brennan To Its Board Of Directors
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Vertex rises after kidney disease drug shows promise in mid-stage study
Brief: Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria